Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INBS NASDAQ:LYRA NASDAQ:MHUA NASDAQ:VERO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINBSIntelligent Bio Solutions$1.55+2.0%$1.67$1.10▼$3.00$13.92M4.59101,889 shs71,859 shsLYRALyra Therapeutics$6.85-2.7%$7.69$3.81▼$37.50$11.27M0.1713,513 shs13,826 shsMHUAMeihua International Medical Technologies$0.37-3.6%$0.41$0.25▼$1.24$11.80M0.7948,627 shs105,131 shsVEROVenus Concept$2.28$2.48$2.10▼$14.50$3.25M0.0942,171 shs14,708 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINBSIntelligent Bio Solutions0.00%-4.32%0.00%-6.63%+19.23%LYRALyra Therapeutics0.00%-2.14%-0.58%-71.79%-52.35%MHUAMeihua International Medical Technologies0.00%-13.07%-8.75%-39.08%-63.86%VEROVenus Concept0.00%+3.17%-6.56%-28.30%-60.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINBSIntelligent Bio Solutions$1.55+2.0%$1.67$1.10▼$3.00$13.92M4.59101,889 shs71,859 shsLYRALyra Therapeutics$6.85-2.7%$7.69$3.81▼$37.50$11.27M0.1713,513 shs13,826 shsMHUAMeihua International Medical Technologies$0.37-3.6%$0.41$0.25▼$1.24$11.80M0.7948,627 shs105,131 shsVEROVenus Concept$2.28$2.48$2.10▼$14.50$3.25M0.0942,171 shs14,708 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINBSIntelligent Bio Solutions0.00%-4.32%0.00%-6.63%+19.23%LYRALyra Therapeutics0.00%-2.14%-0.58%-71.79%-52.35%MHUAMeihua International Medical Technologies0.00%-13.07%-8.75%-39.08%-63.86%VEROVenus Concept0.00%+3.17%-6.56%-28.30%-60.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINBSIntelligent Bio Solutions 0.00N/AN/AN/ALYRALyra Therapeutics 2.00Hold$100.001,359.85% UpsideMHUAMeihua International Medical Technologies 0.00N/AN/AN/AVEROVenus Concept 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VERO, MHUA, INBS, and LYRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025LYRALyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINBSIntelligent Bio Solutions$3.05M4.56N/AN/A$0.41 per share3.78LYRALyra Therapeutics$770K14.63N/AN/A$8.86 per share0.77MHUAMeihua International Medical Technologies$96.90M0.12$0.45 per share0.82$6.34 per share0.06VEROVenus Concept$60.11M0.05N/AN/A$4.30 per share0.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINBSIntelligent Bio Solutions-$10.57M-$2.05N/A4.43N/A-346.22%-231.13%-108.24%11/6/2025 (Estimated)LYRALyra Therapeutics-$93.43M-$29.01N/AN/AN/A-5,043.64%-404.56%-60.06%11/11/2025 (Estimated)MHUAMeihua International Medical Technologies$10.84MN/A0.00∞N/AN/AN/AN/AN/AVEROVenus Concept-$47M-$50.78N/A∞N/A-68.77%-871.77%-61.92%11/13/2025 (Estimated)Latest VERO, MHUA, INBS, and LYRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025Q4 2025INBSIntelligent Bio Solutions-$0.12-$0.37-$0.25-$0.41$4.30 million$0.84 million8/14/2025Q2 2025VEROVenus Concept-$9.72-$8.03+$1.69-$8.03$14.01 million$15.69 million8/12/2025Q2 2025LYRALyra Therapeutics-$5.79-$5.51+$0.28-$5.51$0.18 million$0.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINBSIntelligent Bio SolutionsN/AN/AN/AN/AN/ALYRALyra TherapeuticsN/AN/AN/AN/AN/AMHUAMeihua International Medical TechnologiesN/AN/AN/AN/AN/AVEROVenus ConceptN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINBSIntelligent Bio SolutionsN/A0.770.65LYRALyra TherapeuticsN/A2.782.78MHUAMeihua International Medical TechnologiesN/A5.265.21VEROVenus Concept5.721.100.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINBSIntelligent Bio Solutions32.97%LYRALyra Therapeutics95.62%MHUAMeihua International Medical Technologies1.17%VEROVenus Concept87.41%Insider OwnershipCompanyInsider OwnershipINBSIntelligent Bio Solutions1.54%LYRALyra Therapeutics3.25%MHUAMeihua International Medical Technologies66.56%VEROVenus Concept28.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINBSIntelligent Bio Solutions108.98 million8.84 millionNot OptionableLYRALyra Therapeutics501.65 million1.59 millionOptionableMHUAMeihua International Medical Technologies62031.90 million10.67 millionNot OptionableVEROVenus Concept4101.42 million1.03 millionNot OptionableVERO, MHUA, INBS, and LYRA HeadlinesRecent News About These CompaniesVenus Concept Secures Financial Relief with New AgreementsSeptember 4 at 2:27 AM | msn.comVenus Concept Secures $2M Loan for OperationsAugust 26, 2025 | tipranks.comAnalysts Conflicted on These Healthcare Names: Venus Concept (VERO) and TuHURA Biosciences (HURA)August 22, 2025 | theglobeandmail.comVenus Concept Inc. (NASDAQ:VERO) Q2 2025 Earnings Call TranscriptAugust 16, 2025 | msn.comVenus Concept Reports Q2 2025 Financial ResultsAugust 15, 2025 | msn.comVenus Concept Inc. (VERO) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | seekingalpha.comVenus Concept Amends Loan Agreements for Financial ReliefAugust 14, 2025 | theglobeandmail.comVenus Concept Announces Second Quarter 2025 Financial ResultsAugust 14, 2025 | globenewswire.comVenus Concept to Release Second Quarter of Fiscal Year 2025 Financial Results on August 14, 2025July 16, 2025 | globenewswire.comVenus Concept Inc. to Release Q2 Fiscal 2025 Financial Results on August 14, 2025, with Conference Call DetailsJuly 16, 2025 | quiverquant.comQVERO - Venus Concept Inc Financials - MorningstarJuly 8, 2025 | morningstar.comMVenus Concept Executes Debt-to-Equity Exchange AgreementJuly 1, 2025 | tipranks.comVenus Concept Announces $6.5 Million Debt-to-Equity Exchange TransactionJuly 1, 2025 | globenewswire.comVenus Concept Inc News (VERO) - Investing.comJune 26, 2025 | investing.comVenus Concept Stock Climbs After Stock Offering ClosesJune 9, 2025 | marketwatch.comVenus Concept Inc. Closes Registered Direct Offering and Private Placement Raising Approximately $1.15 MillionJune 9, 2025 | quiverquant.comQVenus Concept Announces Closing of Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesJune 9, 2025 | globenewswire.comVenus Concept To Sell Hair Business To Meta Healthcare In $20M All-Cash DealJune 8, 2025 | nasdaq.comVenus Concept prices $3.45M in direct offering, warrants; shares up over 29%June 7, 2025 | msn.comVenus Concept Stock Is Soaring On Friday - Here's WhyJune 7, 2025 | aol.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeVERO, MHUA, INBS, and LYRA Company DescriptionsIntelligent Bio Solutions NASDAQ:INBS$1.55 +0.03 (+1.97%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.54 -0.01 (-0.58%) As of 09/5/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.Lyra Therapeutics NASDAQ:LYRA$6.85 -0.19 (-2.70%) Closing price 09/5/2025 03:58 PM EasternExtended Trading$6.54 -0.31 (-4.53%) As of 09/5/2025 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.Meihua International Medical Technologies NASDAQ:MHUA$0.36 -0.01 (-3.62%) Closing price 09/5/2025 02:27 PM EasternExtended Trading$0.37 +0.01 (+1.37%) As of 09/5/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Meihua International Medical Technologies Co., Ltd. engages in the manufacture, sells, and marketing of medical consumables in the People's Republic of China. The company offers class I, II, and III disposable medical devices. Its products include non-bottled products, such as brushes and ID bracelets; and polyethylene bottled products, such as eye drop and tablet bottles, as well as electronic pumps. The company also distributes disposable medical devices sourced from other manufacturers to customers in China. In addition, it offers COVID-19 products comprising disposable medical masks. The company serves hospitals, pharmacies, medical institutions, and medical equipment companies. It also exports its products to Europe, North America, South America, Asia, Africa, and Oceania. The company was founded in 1991 and is based in Yangzhou, the People's Republic of China. Meihua International Medical Technologies Co., Ltd. operates as a subsidiary of Bright Accomplish Limited.Venus Concept NASDAQ:VERO$2.28 0.00 (0.00%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.25 -0.03 (-1.32%) As of 09/5/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Union Pacific: Laying the Tracks for America's Industrial Renewal TransDigm’s Edge: From Spare Parts to Sky-High Profits Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
